NYMXF (Nymox Pharmaceutical) E10: $-0.24 (As of Dec. 2024)


What is Nymox Pharmaceutical E10?

Nymox Pharmaceutical NYMXF +9.09% E10 is $-0.24 as of Dec. 2024.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Nymox Pharmaceutical's adjusted earnings per share data for the three months ended in Dec. 2024 was $-0.010. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-0.24 for the trailing ten years ended in Dec. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-06-29), Nymox Pharmaceutical's current stock price is $0.12. Nymox Pharmaceutical's E10 for the quarter that ended in Dec. 2024 was $-0.24. Nymox Pharmaceutical's Shiller PE Ratio of today is .


Nymox Pharmaceutical  (OTCPK:NYMXF) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Nymox Pharmaceutical E10 Related Terms


Nymox Pharmaceutical E10 Historical Data

* Premium members only.

The historical data trend for Nymox Pharmaceutical's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nymox Pharmaceutical E10 Chart

Nymox Pharmaceutical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.26 -0.25 -0.25 -0.25 -0.24

Nymox Pharmaceutical Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Sep24 Dec24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.25 -0.25 -0.25 -0.25 -0.24

NYMXF vs LYRA, RNAZ, TOVX: E10 Comparison

For the Biotechnology subindustry, Nymox Pharmaceutical's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nymox Pharmaceutical Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nymox Pharmaceutical's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Nymox Pharmaceutical's Shiller PE Ratio falls into.



Nymox Pharmaceutical E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Nymox Pharmaceutical's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-0.01/315.6050*315.6050
=-0.010

Current CPI (Dec. 2024) = 315.6050.

Nymox Pharmaceutical Quarterly Data

per share eps CPI Adj_EPS
201409 -0.020 238.031 -0.027
201412 -0.010 234.812 -0.013
201503 0.040 236.119 0.053
201506 -0.140 238.638 -0.185
201509 -0.260 237.945 -0.345
201512 -0.110 236.525 -0.147
201603 -0.080 238.132 -0.106
201606 -0.080 241.018 -0.105
201609 -0.070 241.428 -0.092
201612 -0.050 241.432 -0.065
201703 -0.060 243.801 -0.078
201706 -0.050 244.955 -0.064
201709 -0.090 246.819 -0.115
201712 -0.060 246.524 -0.077
201803 -0.050 249.554 -0.063
201806 -0.040 251.989 -0.050
201809 -0.050 252.439 -0.063
201812 -0.050 251.233 -0.063
201903 -0.040 254.202 -0.050
201906 -0.080 256.143 -0.099
201909 -0.040 256.759 -0.049
201912 -0.040 256.974 -0.049
202003 -0.040 258.115 -0.049
202006 -0.040 257.797 -0.049
202009 -0.060 260.280 -0.073
202012 -0.030 260.474 -0.036
202103 -0.030 264.877 -0.036
202106 -0.050 271.696 -0.058
202109 -0.040 274.310 -0.046
202112 -0.030 278.802 -0.034
202203 -0.060 287.504 -0.066
202206 0.010 296.311 0.011
202209 -0.020 296.808 -0.021
202212 -0.010 296.797 -0.011
202303 -0.020 301.836 -0.021
202306 -0.010 305.109 -0.010
202309 -0.010 307.789 -0.010
202312 -0.060 306.746 -0.062
202409 -0.010 315.301 -0.010
202412 -0.010 315.605 -0.010

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $-0.24 mean?
Nymox Pharmaceutical (NYMXF) has a E10 of $-0.24 as of Dec. 2024. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Nymox Pharmaceutical and its competitors.
Is Nymox Pharmaceutical's E10 too high?
Nymox Pharmaceutical's current E10 is $-0.24.
How does Nymox Pharmaceutical's E10 compare to LYRA and RNAZ?
Nymox Pharmaceutical's E10 of $-0.24 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Nymox Pharmaceutical and its competitors. Nymox Pharmaceutical's current E10 is $-0.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nymox Pharmaceutical stock overvalued right now?
Nymox Pharmaceutical (NYMXF) has a current E10 of $-0.24. The current E10 is $-0.24. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Nymox Pharmaceutical (NYMXF), the current E10 is $-0.24 as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nymox Pharmaceutical Business Description

Address Bay & Deveaux Streets, Nassau, BHS
Nymox Pharmaceutical Corp is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and low-grade localized prostate cancer. The company also has an extensive patent portfolio covering its investigational drug as well as other therapeutic and diagnostic indications. It also has U.S. and patent rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. The company operates in one reportable segment, focused on researching and developing products for the aging population.